Ta­laris Ther­a­peu­tics will hand over its spot on the Nas­daq to Tour­ma­line Bio in a re­verse merg­er to fund tri­als of an ex-Pfiz­er drug it hopes can com­pete with Hori­zon Ther­a­peu­tics and Im­muno­vant.
In Feb­ru­ary, Ta­laris end­ed most work on its stem cell ther­a­pies for kid­ney trans­plant pa­tients and went hunt­ing for al­ter­na­tive paths. The all-stock…